Anti-cancer activity of an acid-labile N-alkylisatin conjugate targeting the transferrin receptor

被引:18
作者
Chandran, Vineesh Indira [1 ,2 ,3 ]
Matesic, Lidia [4 ,5 ]
Locke, Julie M. [6 ]
Skropeta, Danielle [4 ,5 ]
Ranson, Marie [1 ,2 ,3 ]
Vine, Kara L. [1 ,2 ,3 ]
机构
[1] Univ Wollongong, Sch Biol Sci, Wollongong, NSW 2522, Australia
[2] Univ Wollongong, Ctr Med Biosci, Wollongong, NSW 2522, Australia
[3] Univ Wollongong, Illawarra Hlth & Med Res Inst, Wollongong, NSW 2522, Australia
[4] Univ Wollongong, Sch Chem, Wollongong, NSW 2522, Australia
[5] Univ Wollongong, Ctr Med Chem, Wollongong, NSW 2522, Australia
[6] Univ Wollongong, Intelligent Polymer Res Inst, Wollongong, NSW 2522, Australia
关键词
Transferrin receptor; N-alkylisatin; Acid-labile linkers; Ligand-drug conjugates; Targeted drug delivery; CELL-SURFACE GLYCOPROTEIN; IN-VITRO; BREAST-CANCER; DIVIDING CELLS; IRON; RETICULOCYTES; CYTOTOXICITY; EXPRESSION; DENSITY; PROLIFERATION;
D O I
10.1016/j.canlet.2011.10.021
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
We have previously reported a series of pH-sensitive imine-linked N-alkylisatin prodrugs that are stable at pH 7.4, but readily cleaved at pH 4.5. Herein, one of the most potent prodrugs, 5,7-dibromo-N-(p-methoxybenzyl)isatin (NAI), was functionalized with a para-phenylpropionic acid linker, and the resulting NAI-imine prodrug conjugated to transferrin (If) to form a NAI-imine-Tf conjugate. Cytotoxicity assays revealed the conjugate was equipotent to the free drug against MCF-7 breast cancer cells, with clear selectivity patterns based on TfR levels. These results suggest that this novel isatin-based cytotoxin conjugated to a tumor targeting protein via an acid-labile linker warrants further preclinical testing. (C) 2011 Elsevier Ireland Ltd. All rights reserved.
引用
收藏
页码:151 / 156
页数:6
相关论文
共 48 条
[1]  
Aisen P, 1998, MET IONS BIOL SYST, V35, P585
[2]   KINETICS OF INTERACTION BETWEEN RABBIT TRANSFERRIN AND RETICULOCYTES [J].
BAKER, E ;
MORGAN, EH .
BIOCHEMISTRY, 1969, 8 (03) :1133-&
[3]  
Bicamumpaka C, 1998, ONCOL REP, V5, P1381
[4]   Targeted cancer therapy: Conferring specificity to cytotoxic drugs [J].
Chari, Ravi V. J. .
ACCOUNTS OF CHEMICAL RESEARCH, 2008, 41 (01) :98-107
[5]   The transferrin receptor part II: Targeted delivery of therapeutic agents into cancer cells [J].
Daniels, Tracy R. ;
Delgado, Tracie ;
Helguera, Gustavo ;
Penichet, Manuel L. .
CLINICAL IMMUNOLOGY, 2006, 121 (02) :159-176
[6]   Soluble and cell-associated transferrin receptor in lung cancer [J].
Dowlati, A ;
Loo, M ;
Bury, T ;
Fillet, G ;
Beguin, Y .
BRITISH JOURNAL OF CANCER, 1997, 75 (12) :1802-1806
[7]  
FAULK WP, 1980, LANCET, V2, P390
[8]   STUDIES OF THE TRANSFERRIN RECEPTOR ON BOTH HUMAN RETICULOCYTES AND NUCLEATED HUMAN-CELLS IN CULTURE - COMPARISON OF FACTORS REGULATING RECEPTOR DENSITY [J].
FRAZIER, JL ;
CASKEY, JH ;
YOFFE, M ;
SELIGMAN, PA .
JOURNAL OF CLINICAL INVESTIGATION, 1982, 69 (04) :853-865
[9]   Targeted drug conjugates: principles and progress [J].
Garnett, MC .
ADVANCED DRUG DELIVERY REVIEWS, 2001, 53 (02) :171-216
[10]   TRANSFERRIN RECEPTORS IN HUMAN-TISSUES - THEIR DISTRIBUTION AND POSSIBLE CLINICAL RELEVANCE [J].
GATTER, KC ;
BROWN, G ;
TROWBRIDGE, IS ;
WOOLSTON, RE ;
MASON, DY .
JOURNAL OF CLINICAL PATHOLOGY, 1983, 36 (05) :539-545